Your SlideShare is downloading. ×
0
C1_2 Michael Saag Chronic Disease in Longer-Term HIV Patients
C1_2 Michael Saag Chronic Disease in Longer-Term HIV Patients
C1_2 Michael Saag Chronic Disease in Longer-Term HIV Patients
C1_2 Michael Saag Chronic Disease in Longer-Term HIV Patients
C1_2 Michael Saag Chronic Disease in Longer-Term HIV Patients
C1_2 Michael Saag Chronic Disease in Longer-Term HIV Patients
C1_2 Michael Saag Chronic Disease in Longer-Term HIV Patients
C1_2 Michael Saag Chronic Disease in Longer-Term HIV Patients
C1_2 Michael Saag Chronic Disease in Longer-Term HIV Patients
C1_2 Michael Saag Chronic Disease in Longer-Term HIV Patients
C1_2 Michael Saag Chronic Disease in Longer-Term HIV Patients
C1_2 Michael Saag Chronic Disease in Longer-Term HIV Patients
C1_2 Michael Saag Chronic Disease in Longer-Term HIV Patients
C1_2 Michael Saag Chronic Disease in Longer-Term HIV Patients
C1_2 Michael Saag Chronic Disease in Longer-Term HIV Patients
C1_2 Michael Saag Chronic Disease in Longer-Term HIV Patients
C1_2 Michael Saag Chronic Disease in Longer-Term HIV Patients
C1_2 Michael Saag Chronic Disease in Longer-Term HIV Patients
C1_2 Michael Saag Chronic Disease in Longer-Term HIV Patients
C1_2 Michael Saag Chronic Disease in Longer-Term HIV Patients
C1_2 Michael Saag Chronic Disease in Longer-Term HIV Patients
C1_2 Michael Saag Chronic Disease in Longer-Term HIV Patients
C1_2 Michael Saag Chronic Disease in Longer-Term HIV Patients
C1_2 Michael Saag Chronic Disease in Longer-Term HIV Patients
C1_2 Michael Saag Chronic Disease in Longer-Term HIV Patients
C1_2 Michael Saag Chronic Disease in Longer-Term HIV Patients
C1_2 Michael Saag Chronic Disease in Longer-Term HIV Patients
C1_2 Michael Saag Chronic Disease in Longer-Term HIV Patients
C1_2 Michael Saag Chronic Disease in Longer-Term HIV Patients
C1_2 Michael Saag Chronic Disease in Longer-Term HIV Patients
C1_2 Michael Saag Chronic Disease in Longer-Term HIV Patients
C1_2 Michael Saag Chronic Disease in Longer-Term HIV Patients
C1_2 Michael Saag Chronic Disease in Longer-Term HIV Patients
C1_2 Michael Saag Chronic Disease in Longer-Term HIV Patients
C1_2 Michael Saag Chronic Disease in Longer-Term HIV Patients
C1_2 Michael Saag Chronic Disease in Longer-Term HIV Patients
C1_2 Michael Saag Chronic Disease in Longer-Term HIV Patients
C1_2 Michael Saag Chronic Disease in Longer-Term HIV Patients
C1_2 Michael Saag Chronic Disease in Longer-Term HIV Patients
C1_2 Michael Saag Chronic Disease in Longer-Term HIV Patients
C1_2 Michael Saag Chronic Disease in Longer-Term HIV Patients
C1_2 Michael Saag Chronic Disease in Longer-Term HIV Patients
C1_2 Michael Saag Chronic Disease in Longer-Term HIV Patients
C1_2 Michael Saag Chronic Disease in Longer-Term HIV Patients
C1_2 Michael Saag Chronic Disease in Longer-Term HIV Patients
C1_2 Michael Saag Chronic Disease in Longer-Term HIV Patients
C1_2 Michael Saag Chronic Disease in Longer-Term HIV Patients
C1_2 Michael Saag Chronic Disease in Longer-Term HIV Patients
C1_2 Michael Saag Chronic Disease in Longer-Term HIV Patients
C1_2 Michael Saag Chronic Disease in Longer-Term HIV Patients
C1_2 Michael Saag Chronic Disease in Longer-Term HIV Patients
C1_2 Michael Saag Chronic Disease in Longer-Term HIV Patients
C1_2 Michael Saag Chronic Disease in Longer-Term HIV Patients
C1_2 Michael Saag Chronic Disease in Longer-Term HIV Patients
C1_2 Michael Saag Chronic Disease in Longer-Term HIV Patients
C1_2 Michael Saag Chronic Disease in Longer-Term HIV Patients
C1_2 Michael Saag Chronic Disease in Longer-Term HIV Patients
C1_2 Michael Saag Chronic Disease in Longer-Term HIV Patients
C1_2 Michael Saag Chronic Disease in Longer-Term HIV Patients
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

C1_2 Michael Saag Chronic Disease in Longer-Term HIV Patients

464

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
464
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
12
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  1. Strategies forAntiretroviral Therapy:When to Start, How to Finish <br />Michael S. Saag, MDProfessor of MedicineThe University of Alabama at Birmingham<br />The International AIDS Society–USA<br />
  2. M Saag, UAB<br />
  3. Latently Infected CD4+ Lymphocytes<br />HIV Infected Cells<br />HIV virions<br />Antiretroviral Rx<br />Uninfected Activated CD4+ Lymphocytes<br />Uninfected Resting CD4+ Lymphocytes<br />M Saag, UAB<br />
  4. At steady state, when an actively producing cell dies, it is replaced by how many newly infected cells?<br />One<br />Twenty-five<br />One hundred<br />One thousand<br />It depends on the viral load<br />[Default]<br />[MC Any]<br />[MC All]<br />
  5. M Saag, UAB<br />
  6. VL = 100,000<br />
  7. VL < 50<br />
  8. Goals of Antiretroviral Therapy<br />Prevent Clinical Progression<br />Prevent Resistance<br />
  9. NEJM, 1993<br />
  10. Impact of Replication on Resistance<br />Likelihood of Resistance<br />High<br />Degree of Suppression<br />
  11. Case 1<br />30 yo white man<br />Diagnosed on routine insurance examination<br />PMHx remarkable for HTN, diet controlled<br />No medications<br />Understands treatment issues and wants to begin therapy if you think it is appropriate<br />
  12. If his viral load is 30,000 c/ml, at which CD4 count would you recommend starting therapy?<br />750 cells / ul<br />500 cells / ul<br />350 cells / ul<br />300 cells / ul<br />250 cells / ul<br />≤ 200 cells / ul<br />Would observe <br />Would treat at any CD4 count<br />[Default]<br />[MC Any]<br />[MC All]<br />
  13. When To Start Treatment? – Summary of Current Guidelines<br />symptoms<br />
  14. CD4 Count at Initiation of ARV 2003-2005<br />Egger M, 14th CROI; 2007; Abstract 62.<br />
  15. Which of the following convinces you MOST to start therapy earlier in course of HIV infection?<br />Cohort Study Results (NA-ACCORD / ART-CC<br />Consequences of unchecked viral replication (Inflammation / Harm)<br />Improved tolerability / convenience of newer ARV regimens<br />Treatment reduces transmission of HIV <br />Cost Savings<br />I have my own personal reasons!<br />[Default]<br />[MC Any]<br />[MC All]<br />
  16. Inverse Probability Weighted Cox Regression Multivariate Analysis<br /><ul><li> Results were similar when restricting the analysis to the 77% of </li></ul> participants with baseline HIV RNA data<br /><ul><li> Adjusted RH for deferral vs. immediate treatment was also 1.7</li></ul> 95% C.I. 1.4, 2.2; p <0.0001<br /><ul><li> HIV RNA was not an independent predictor of mortality</li></li></ul><li>4<br />2<br /> Hazard Ratio for AIDS or Death<br />1<br />.5<br /> 0<br /> 100<br /> 200<br /> 300<br /> 400<br /> 500<br />CD4 threshold (cells/mm3)<br />Hazard ratios for AIDS or death, adjusted for lead times and unseen events<br />
  17. A Randomized Clinical Trial of Early Versus Standard Antiretroviral Therapy for HIV-infected Patients with a CD4 T Cell Count of 200 – 350 cells/ml (CIPRAHT001)<br />Daniel Fitzgerald, MD<br />The GHESKIO Centers, Haiti<br />Weill Cornell Medical College, USA<br />
  18. Baseline Characteristics<br />
  19. Clinical Endpoints<br />
  20. Case 1<br />30 yo white man<br />Diagnosed on routine insurance examination<br />PMHx remarkable for HTN, diet controlled<br />No medications<br />Understands treatment issues and wants to begin therapy if you think it is appropriate<br /> VL is 30,000 c/mL<br /> CD4 is 650 cells/ul<br />
  21. If his viral load is 30,000 c/ml, and his CD4 count is 650 cells/ul, at what age would you recommend starting therapy?<br />20 yrs<br />30 yrs<br />40 yrs<br />50 yrs<br />60 yrs<br />70 yrs<br />Would treat at any age<br />Would not treat<br />[Default]<br />[MC Any]<br />[MC All]<br />
  22. Relative Time on Treatment…<br />40 years on Rx<br />CD4 650/ul<br />35 years on Rx<br />5 years<br />CD4 500/ul<br /> 30 35 40 45 50 55 60 65 70<br />AGE (years)<br />
  23. <ul><li>Cohort Study Results (NA-ACCORD / ART-CC)
  24. Consequences of unchecked viral replication (Inflammation / Harm)
  25. Improved tolerability / convenience of newer ARV regimens
  26. Treatment reduces transmission of HIV
  27. Cost Savings
  28. I have my own personal reasons!</li></li></ul><li>Relative Time on Treatment…<br />40 years on Rx<br />HARM?<br />CD4 650/ul<br />35 years on Rx<br />5 years<br />CD4 500/ul<br /> 30 35 40 45 50 55 60 65 70<br />AGE (years)<br />
  29. So ….what is the harm?(Pick the most compelling reason)<br />Destruction of lymphoid tissue<br />Inflammation<br />Increased Cardiovascular events<br />Increased incidence of certain malignancies<br />Increased ‘aging’<br />Accelerated cognitive decline<br />Another reason<br />[Default]<br />[MC Any]<br />[MC All]<br />
  30. Question 1 – Cognitive Differences Detected?<br />*<br />*<br />Lower scores reflect better function.<br />Trails A - Sig. Dif. for Age and HIV<br />Trails B – Sig. Dif. For HIV<br />
  31. Question 1 – Cognitive Differences Detected?<br />*<br />Higher scores reflect better function.<br />Finger Tapping - Sig. Dif. for HIV<br />
  32. Question 2 – Differences in TIADLs in Older and Younger Adults with and without HIV?<br />*<br />*<br />Lower scores reflects better function.<br />Age, HIV, and AgeXHIV effects observed.<br />
  33. Question 2 – Differences in TIADLs in Older and Younger Adults with and without HIV?<br />*<br />*<br />Lower scores reflects better function.<br />Age, HIV, and AgeXHIV effects observed for Total Score.<br />
  34. <ul><li>Cohort Study Results (NA-ACCORD / ART-CC)
  35. Consequences of unchecked viral replication (Inflammation / Harm)
  36. Improved tolerability / convenience of newer ARV regimens
  37. Treatment reduces transmission of HIV
  38. Cost Savings
  39. I have my own personal reasons!</li></li></ul><li>Willig, et al, AIDS, 2008<br />
  40. 1st Line ARV Therapy: 2003- 2007<br />McKinnell, et al, AIDS Pt Care & STDs, 2010<br />
  41. Does treating HIV lead to reduced transmission of HIV?<br />Yes<br />No<br />Depends on the sexual practices!<br />[Default]<br />[MC Any]<br />[MC All]<br />
  42. Most New Infections Transmitted by Persons who Do Not Know Their Status<br />account for…<br />~25% Unaware of Infection<br />~54% New Infections<br />~75% Aware of Infection<br />~46% of New Infections<br />Source: G. Marks et al. AIDS 2006<br />
  43. <400<br /><400<br /><400<br />>50 000<br />>50 000<br />>50 000<br />400-3499<br />400-3499<br />400-3499<br />3500-9999<br />3500-9999<br />3500-9999<br />10 000-49 999<br />10 000-49 999<br />10 000-49 999<br />TNT: Based on the association of viral load and HIV transmission risk<br />30<br />Female-to-Male<br />Transmission<br />Male-to-Female<br />Transmission<br />All subjects<br />25<br />20<br />15<br />Transmission rate per 100 Person-Years <br />10<br />5<br />0<br />Viral load (HIV-1 RNA copies/mL) and HIV transmission<br />Quinn TC, et al.NEJM 2000; also Fideli U, et al. AIDS Res Hum Retrovir 2001<br />
  44. <ul><li>Cohort Study Results (NA-ACCORD / ART-CC)
  45. Consequences of unchecked viral replication (Inflammation / Harm)
  46. Improved tolerability / convenience of newer ARV regimens
  47. Treatment reduces transmission of HIV
  48. Cost Savings
  49. I have my own personal reasons!</li></li></ul><li>Prevention of Transmission<br />TEST and TREAT <br />Testing and Linkage to Care (TLC+)<br />National AIDS Strategy…<br />
  50. <ul><li>Cohort Study Results (NA-ACCORD / ART-CC)
  51. Consequences of unchecked viral replication (Inflammation / Harm)
  52. Improved tolerability / convenience of newer ARV regimens
  53. Treatment reduces transmission of HIV
  54. Cost Savings
  55. I have my own personal reasons!</li></li></ul><li>Cost-Effectiveness of Early vs. Deferred ART<br /> “Starting ART earlier … rather than later … is a cost-effective strategy (by the generally accepted benchmark in the US).”<br />Mauskopf JA, et al. JAIDS 2005;39:562-569.<br />
  56. Case 1<br />30 yo white man<br />Diagnosed on routine insurance examination<br />PMHx remarkable for HTN, diet controlled<br />No medications<br />Understands treatment issues and wants to begin therapy if you think it is appropriate<br />
  57. If his viral load is 30,000 c/ml, at which CD4 count would you recommend starting therapy?<br />750 cells / ul<br />500 cells / ul<br />350 cells / ul<br />300 cells / ul<br />250 cells / ul<br />≤ 200 cells / ul<br />Would observe<br />Would treat at any CD4 count<br />[Default]<br />[MC Any]<br />[MC All]<br />
  58. START (Strategic Timing of ART) Study<br />INSIGHT Network: multinational<br />Study population: adults with CD4 >500<br />Study treatment:<br />Immediate ART<br />CD4 <350<br />Study endpoints:<br />Serious AIDS-defining illness, non-AIDS illness, death<br />Sample size:<br />N=900 (pilot for feasibility)<br />N=4000 (definitive)<br />Duration: ~6 yrs.<br />http://insight.ccbr.umn.edu/official_documents/START/protocol_documents/START_ProtocolSynopsis.pdf<br />
  59. CD4 Count at Initiation of ARV 2003-2005<br />Egger M, 14th CROI; 2007; Abstract 62.<br />
  60. Which of the following convinces you MOST to start therapy earlier in course of HIV infection?<br />Cohort Study Results (NA-ACCORD / ART-CC)<br />Consequences of unchecked viral replication (inflammation / harm)<br />Improved tolerability / convenience of newer ARV regimens<br />Treatment reduces transmission of HIV<br />Cost savings<br />I have my own personal reasons!<br />[Default]<br />[MC Any]<br />[MC All]<br />
  61. Case 1<br />30 yo White Male<br />Diagnosed on routine insurance examination<br />PMHx remarkable for HTN, diet controlled<br />No medications<br />Understands treatment issues and wants to begin therapy if you think it is appropriate<br />
  62. If his viral load is 30,000 c/ml, at which CD4 count would you recommend starting therapy?<br />750 cells / ul<br />500 cells / ul<br />350 cells / ul<br />300 cells / ul<br />250 cells / ul<br />≤200 cells / ul<br />Would observe<br />Would treat at any CD4 count<br />[Default]<br />[MC Any]<br />[MC All]<br />
  63. END of SESSION 1<br />

×